These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Hüttmann A; Schirsafi K; Seeber S; Bojko P J Cancer Res Clin Oncol; 2005 Mar; 131(3):152-6. PubMed ID: 15583936 [TBL] [Abstract][Full Text] [Related]
3. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967 [TBL] [Abstract][Full Text] [Related]
5. A systematic review of available clinical evidence - filgrastim compared with lenograstim. Sourgens H; Lefrère F Int J Clin Pharmacol Ther; 2011 Aug; 49(8):510-8. PubMed ID: 21781651 [TBL] [Abstract][Full Text] [Related]
6. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384 [TBL] [Abstract][Full Text] [Related]
7. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Dunn CJ; Goa KL Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839 [TBL] [Abstract][Full Text] [Related]
8. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Orciuolo E; Buda G; Marturano E; Mauro E; Milone G; Cangialosi C; Di Renzo N; Pastore D; Specchia G; De Paolis MR; Mazza P; Pietrantuono G; Petrini M Leuk Res; 2011 Jul; 35(7):899-903. PubMed ID: 21134693 [TBL] [Abstract][Full Text] [Related]
9. Colony stimulating factors: G-CSFs--filgrastim (Neupogen) and lenograstim (Granocyte). MacConnachie AM Intensive Crit Care Nurs; 1998 Feb; 14(1):49-50. PubMed ID: 9652261 [TBL] [Abstract][Full Text] [Related]
10. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference? Höglund M Med Oncol; 1998 Dec; 15(4):229-33. PubMed ID: 9951685 [TBL] [Abstract][Full Text] [Related]
11. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group. Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Felty's syndrome with the haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF). Stanworth SJ; Bhavnani M; Chattopadhya C; Miller H; Swinson DR QJM; 1998 Jan; 91(1):49-56. PubMed ID: 9519212 [TBL] [Abstract][Full Text] [Related]
13. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Kim IH; Park SK; Suh OK; Oh JM Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447 [TBL] [Abstract][Full Text] [Related]
14. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany. Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299 [TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench. Hui CH; Hughes TP Leuk Lymphoma; 2006 Sep; 47(9):1721-3. PubMed ID: 17064975 [No Abstract] [Full Text] [Related]
17. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286 [No Abstract] [Full Text] [Related]
18. The use of granulocyte colony stimulating factoR (G-CSF) (filgrastim) alone in the mobilization of stem cell in the autologous stem cell transplantation. Talhi S; Osmani S; Brahimi M; Yafour N; Bouhass R; Arabi A; Bekadja MA Transfus Apher Sci; 2013 Aug; 49(1):97-9. PubMed ID: 23830594 [No Abstract] [Full Text] [Related]
19. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321 [TBL] [Abstract][Full Text] [Related]
20. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Lefrère F; Bernard M; Audat F; Cavazzana-Calvo M; Belanger C; Hermine O; Arnulf B; Buzyn A; Varet B Leuk Lymphoma; 1999 Nov; 35(5-6):501-5. PubMed ID: 10609787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]